Henlius Gains NMPA IND Approval for HLX48, a Bispecific c-Met/EGFR Antibody-Drug Conjugate for Solid Tumors
FirstWord Pharma China Overview Shanghai Henlius Biotech, Inc. announced that its self-developed c-Met/EGFR bispecific antibody-drug conjugate (ADC), HLX48, has received Investigational New Drug (IND) approval from China's National Medic...
